FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 28-Feb 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4696188010 | Pyrimethamine 12.5 mg and sulfadoxine 250 mg tablet for oral suspension | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4696189019 | Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5259839015 | Pyrimethamine 12.5 mg and sulfadoxine 250 mg dispersible oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Is a | Pyrimethamine and sulfadoxine only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has manufactured dose form | Tablet for conventional release oral suspension (dose form) | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Plays role | Antibacterial therapeutic role (role) | false | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Plays role | Antimalarial therapeutic role | false | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Pyrimethamine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Pyrimethamine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Sulfadoxine | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Sulfadoxine | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets